| Authors: |
Fedoriw A; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Shi L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., O'Brien S; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Smitheman KN; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Wang Y; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hou J; Department of Biology and Biochemistry, University of Houston, Houston, Texas., Sherk C; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Rajapurkar S; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Laraio J; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Williams LJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Xu C; Department of Biology and Biochemistry, University of Houston, Houston, Texas., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng Q; Department of Biology and Biochemistry, University of Houston, Houston, Texas., Bedford MT; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, Texas., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Barbash O; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Kruger RG; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Mohammad HP; Tumor Cell Targeting Research Unit, GlaxoSmithKline, Collegeville, Pennsylvania., Peng W; Department of Biology and Biochemistry, University of Houston, Houston, Texas. |
